Ebglyss is not appropriate for patients with a known allergy to lebrikizumab or any of its ingredients. It is also not recommended for patients under 12 years of age, or for patients ages 12 and older who weigh less than 88 pounds (40 kg).

Because Ebglyss modulates immune function, live vaccines should not be given during treatment. Your Honeydew provider will review your vaccination history and advise on completing any age-appropriate vaccinations before starting Ebglyss.

From an insurance standpoint, many plans require step therapy, meaning documentation that topical treatments were tried and failed, before approving a biologic. If you're earlier in your eczema treatment journey and haven't yet tried prescription topicals, your Honeydew provider can help structure a treatment path that satisfies insurer requirements and gets you to Ebglyss efficiently if it's the right goal.

Yes. Ebglyss can be used with or without topical corticosteroids, and many patients use both,  particularly during the initial treatment phase before Ebglyss reaches full effect. Topical calcineurin inhibitors (such as tacrolimus) may also be used alongside Ebglyss, though providers typically reserve these for specific sensitive areas such as the face, neck, and skin folds.

Your Honeydew dermatologist will advise you on which combination approach is appropriate for your skin and help you phase out or reduce topical treatments as Ebglyss takes effect during maintenance. If your eczema flares during maintenance dosing, a temporary return to topical rescue medications is common and expected. Your provider will guide you through this as part of your ongoing care plan.

Conjunctivitis (pink eye) is the most commonly reported eye-related side effect associated with Ebglyss and other IL-13 inhibitor biologics. In clinical trials, conjunctivitis occurred in a minority of patients and was classified as mild to moderate in severity in most cases. The majority of patients who experienced it were able to continue treatment with the help of lubricating eye drops or corticosteroid eye drops under provider guidance.

If you develop redness, irritation, discharge, or discomfort in your eyes while taking Ebglyss, contact your Honeydew care team promptly. In most cases these symptoms are manageable without stopping treatment, but your provider will assess whether an ophthalmology referral is appropriate.

Informing your Honeydew provider about any pre-existing eye conditions before starting Ebglyss is also important, as it helps establish a baseline for monitoring.

Yes. Ebglyss is FDA-approved for patients ages 12 and older who weigh at least 88 pounds (40 kg / approximately 40 kg). Both conditions — the age threshold and the weight threshold — must be met for Ebglyss to be prescribed.

The dosing for eligible adolescents is the same as for adults: an initial dose of 500 mg (two injections) at weeks 0 and 2, followed by 250 mg every 2 weeks until adequate eczema control is achieved, then maintenance dosing every 4 weeks. For adolescents who have not yet reached the 88-pound threshold, your Honeydew provider can discuss alternative biologic options — including Dupixent, which has no minimum weight requirement for its 12-and-older approval.

As with all patients under 18, a parent or guardian must be part of the initial consultation, which Honeydew facilitates through our virtual care process.

Yes. Ebglyss is FDA-approved for patients ages 12 and older who weigh at least 88 pounds (40 kg / approximately 40 kg). Both conditions — the age threshold and the weight threshold — must be met for Ebglyss to be prescribed.

The dosing for eligible adolescents is the same as for adults: an initial dose of 500 mg (two injections) at weeks 0 and 2, followed by 250 mg every 2 weeks until adequate eczema control is achieved, then maintenance dosing every 4 weeks. For adolescents who have not yet reached the 88-pound threshold, your Honeydew provider can discuss alternative biologic options — including Dupixent, which has no minimum weight requirement for its 12-and-older approval.

As with all patients under 18, a parent or guardian must be part of the initial consultation, which Honeydew facilitates through our virtual care process.

Ebglyss (lebrikizumab) and Adbry (tralokinumab) are both IL-13 selective biologics approved for moderate to severe atopic dermatitis in patients ages 12 and older, and both are prescribed by Honeydew's dermatologists. They share a similar mechanism but differ in a few meaningful ways:

Dosing frequency: Both medications require every-2-week injections during the initial phase. Adbry's minimum maintenance schedule is every 4 weeks. Ebglyss goes further — eligible patients may reduce to every 8 weeks during maintenance, potentially making it the less-frequent injection option of the two for patients who achieve strong eczema control.

Weight requirement: Adbry has no minimum weight requirement for its 12-and-older approval. Ebglyss requires patients to weigh at least 88 pounds (40 kg). This distinction matters when prescribing for adolescents who may not yet meet the weight threshold.

Binding mechanism: Both drugs block IL-13, but they bind to it differently. Laboratory studies suggest lebrikizumab (Ebglyss) has higher binding affinity and a slower rate of dissociation than tralokinumab (Adbry), which may contribute to its effective monthly dosing schedule. There are no published head-to-head clinical trials comparing the two directly.

Insurance coverage: Formulary placement varies significantly between Adbry and Ebglyss depending on the insurance plan. Honeydew will help identify which is better covered under your specific plan and which savings programs apply.

Your Honeydew dermatologist will consider your full treatment history, insurance, and individual skin response when recommending between these options.

Many patients notice early improvement, particularly in itching and sleep disruption, within the first 2 weeks of starting Ebglyss. More significant eczema clearance, including reduction of widespread redness, plaques, and flares, typically becomes visible by week 16 (approximately 4 months). In the ADvocate 1 and 2 clinical trials, approximately 70 to 75% of patients achieved clear or nearly clear skin at week 16.

Long-term results are strong: over 70% of patients who responded at week 16 maintained their eczema improvement at 52 weeks, and long-term extension data shows durable disease control out to 4 years with continued treatment.

If your symptoms haven't improved meaningfully by week 16, contact your Honeydew care team. Your provider may recommend continuing every-2-week dosing a little longer before reassessing, or may discuss whether a different biologic or treatment combination is a better fit.

Yes, Honeydew's board-certified dermatologists prescribe and manage Ebglyss entirely online. No in-person office visit is required at any stage. You complete a brief medical questionnaire and share your skin history and photos, and a licensed dermatology provider reviews your case. If a video consult is needed, it can typically be scheduled within 48 hours.

From there, your dermatologist confirms your eligibility, manages prior authorization with your insurance, and coordinates with a specialty pharmacy to arrange delivery. Ongoing care, including response assessments at week 16 when your dosing schedule may adjust, monitoring for side effects, and refill coordination, is all managed virtually through Honeydew.

Yes, like most specialty biologic medications, Ebglyss requires prior authorization from your insurance before coverage kicks in. Many plans also require step therapy, meaning you may need to show that topical prescription treatments — and in some cases, other biologics like Dupixent — were tried first before Ebglyss is approved. Prior authorization typically takes 2 to 4 weeks once submitted.

This is often the most stressful and time-consuming part of starting a specialty biologic and it's something Honeydew handles entirely on your behalf. Your provider prepares and submits the prior authorization documentation, follows up with your insurer, and coordinates the specialty pharmacy so your treatment doesn't stall in paperwork. If your initial authorization is denied, we guide you through the appeals process. In the meantime, the Ebglyss Savings Card's non-covered benefit program may allow you to start treatment at $25/month while your coverage appeal is in progress.

Getting Ebglyss prescribed online through Honeydew doesn't mean managing insurance alone — we take care of the access process from start to finish.

Yes, and this is one of Ebglyss's most important differentiators from other eczema biologics. Here's the full schedule:

Loading phase (Weeks 0–16+): You begin with an initial dose of 500 mg (two 250 mg injections given at the same time) at Week 0 and Week 2. After that, you continue with a single 250 mg injection every 2 weeks until Week 16 or until your eczema is adequately controlled.

Maintenance phase: Once adequate clinical response is achieved, maintenance dosing drops to a single 250 mg injection every 4 weeks (once monthly). For patients who maintain strong eczema control, dosing may be further reduced to every 8 weeks, meaning as few as 6 injections per year during the maintenance phase.

This every-8-week option is currently unique to Ebglyss among FDA-approved eczema biologics and represents a meaningful quality-of-life advantage for patients who achieve and maintain good eczema control. Your Honeydew dermatologist will assess your response at 16 weeks and work with you to determine the right maintenance schedule.

Ebglyss comes as a prefilled injection pen or prefilled syringe and is self-administered at home. Your specialist pharmacy will provide injection training materials before your first dose.

Ebglyss (lebrikizumab) and Dupixent (dupilumab) are both FDA-approved biologic injections for moderate to severe atopic dermatitis, and both are prescribed by Honeydew's board-certified dermatologists. Here's how they compare across the factors that matter most to patients:

How they work: Dupixent blocks both IL-4 and IL-13, two proteins that drive eczema inflammation. Ebglyss specifically targets IL-13 only, using a different binding approach. Both produce meaningful eczema clearance in clinical trials, with indirect comparison studies suggesting Ebglyss may offer comparable or superior long-term efficacy for some patients.

Dosing — Ebglyss's biggest advantage: After an initial loading phase, Dupixent is given every 2 weeks with no option to reduce frequency for eczema. Ebglyss, by contrast, steps down to once-monthly (every 4 weeks) maintenance dosing after the initial phase — and eligible patients may further reduce to every 8 weeks, potentially as few as 6 injections per year. For patients who want the least frequent injection schedule possible, Ebglyss has a meaningful edge.

Age and weight eligibility: Dupixent is FDA-approved for patients as young as 6 months old with no weight requirement. Ebglyss is approved for patients ages 12 and older who weigh at least 88 pounds (40 kg). If you need a biologic for a young child or a teenager who doesn't yet meet the weight threshold, Dupixent is likely the more appropriate option.

Other conditions: Dupixent is approved for multiple conditions including asthma, nasal polyps, eosinophilic esophagitis, and prurigo nodularis in addition to eczema. Ebglyss is currently approved only for atopic dermatitis. If you have co-occurring conditions that Dupixent also treats, that may factor into your provider's recommendation.

Eye side effects: Both medications can cause conjunctivitis. Neither has a clearly established advantage over the other in terms of overall eye-related side effect rates, though the clinical profiles differ slightly. Your Honeydew provider will monitor for eye symptoms throughout treatment.

Since Honeydew prescribes both medications, your dermatologist will review your full history, insurance coverage, and treatment goals to recommend which is the better fit for your specific situation.

Ebglyss's list price makes it look expensive at first, but most patients pay far less, and the savings structure for Ebglyss is actually among the most patient-friendly of any eczema biologic currently available. Here's exactly how it breaks down:

With commercial insurance that covers Ebglyss: Eligible patients can use the Ebglyss Savings Card from Eli Lilly to pay as little as $5 per monthly prescription fill, making it one of the most affordable specialty biologics for commercially insured patients. The card covers up to 14 prescription fills per calendar year.

With commercial insurance that does not yet cover Ebglyss: If your insurance doesn't cover Ebglyss, you may still pay as little as $25 per monthly supply through the non-covered benefit tier of the Ebglyss Savings Card, provided a prior authorization has been submitted and a coverage denial is on file. This program is designed specifically to keep patients on treatment while the appeals process moves forward.

Without commercial insurance: If you have financial need and limited or no prescription coverage, the Lilly Cares Foundation Patient Assistance Program may provide Ebglyss at no cost for qualifying patients based on income and eligibility requirements.

Note that the savings card is not available to patients covered by Medicare, Medicaid, TRICARE, VA, or other government-funded programs. Medicare patients should ask their Honeydew provider about the Medicare Part D Extra Help program and other available options.

Honeydew's membership fee (starting at $25/month on an annual plan) is separate from medication costs and is HSA/FSA eligible. We handle insurance verification, prior authorization submission, and specialty pharmacy coordination on your behalf — so you're never navigating the cost process on your own.

Ebglyss may be appropriate for people with moderate to severe eczema that isn’t well controlled with topical treatments. Your provider will determine eligibility.

Ebglyss is given as a subcutaneous injection, typically every few weeks based on your treatment plan.

Ebglyss is often used long term to maintain eczema control. Treatment duration depends on response and provider guidance.

Common side effects include injection-site reactions and eye irritation. Your provider monitors safety throughout treatment.

No. Ebglyss does not require pregnancy testing or special enrollment programs. Your provider will review safe use based on your medical history.

If you or your child is under the age of 18, a parent or guardian should be part of the initial consultation. In circumstances where this is not possible, please contact info@honeydewcare.com and we will assist you with alternate ways to establish parental consent.

We will run the prescriptions through your insurance and help you find the lowest costs out there. The membership fee and any products are also eligible for HSA or FSA reimbursement.

We offer comprehensive support for our patients, including access to experienced providers, assistance with lab orders and the iPledge program (when needed), unlimited support, and progress tracking.